FOLH1 and neoplasm: 64Cu-PSMA-617 also has a lower hepatic uptake than 64Cu-DOTHA2-PSMA, but its tumor-to-liver ratios are lower given its low tumoral uptake (based on the results from dos Santos et al. [15]).